WS #17057
Moderna provided strong Q3 insights, forecasting 15-25% revenue growth for 2026 and targeting $8.1B-$8.3B in year-end cash, signaling robust demand for its vaccines and therapeutics. In contrast, Intellia reported quiet Q3 results, with investor attention shifting to the March 2027 approval decision for its lead candidate. The divergence highlights the bifurcation in biotech, where cash-rich, diversified firms outperform early-stage developers awaiting regulatory catalysts.
Biotech Earnings & Guidance
Moderna provided strong Q3 insights, forecasting 15-25% revenue growth for 2026 and targeting $8.1B-$8.3B in year-end cash, signaling robust demand for its vaccines and therapeutics. In contrast, Intellia reported quiet Q3 results, with investor attention shifting to the March 2027 approval decision for its lead candidate. The divergence highlights the bifurcation in biotech, where cash-rich, diversified firms outperform early-stage developers awaiting regulatory catalysts.